Cipla to further invest Rs. 42 crore in GoApptiv
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expands patient reach to remotest towns by furthering investment in GoApptiv
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
This acquisition marks Max Healthcare's entry into Lucknow
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Express Scripts to add Zepbound to National Preferred Formulary
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Subscribe To Our Newsletter & Stay Updated